CD47 - SIRPa

CD47 is a transmembrane protein that is expressed on the surface of cells and serves as a “self” marker, helping to distinguish healthy cells from foreign cells. SIRPa is an inhibitory receptor found on immune cells such as macrophages and dendritic cells. When CD47 binds to SIRPa, it sends a signal to the immune cells to not attack the healthy cells.

Antibodies are proteins produced by the immune system to specifically recognize and bind to foreign molecules, such as antigens. Antibodies can be used to target CD47-SIRPa, as they are able to recognize and bind to the CD47 molecule. This can be used to block the interaction between CD47 and SIRPa, thus preventing the signal from being sent to the immune cells and allowing them to attack the healthy cells.

CD47-SIRPa has become a promising drug target for a variety of cancer types. By blocking the interaction between CD47 and SIRPa, the immune cells can be activated to attack the cancer cells. This approach is known as “immune checkpoint blockade” and has been shown to be effective in clinical trials.

ProteoGenix is a biotechnology company that specializes in the development of antibodies against CD47-SIRPa. They have developed a range of antibodies that can be used to target CD47-SIRPa for research and therapeutic applications. These antibodies can be used to modulate the interaction between CD47 and SIRPa, thus enabling the immune cells to attack the cancer cells.